Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an announcement.
Shanghai Junshi Biosciences Co., Ltd. has announced the approval of its investigational new drug, JS213, for clinical trials by the National Medical Products Administration. JS213, a PD-1 and interleukin-2 bifunctional antibody fusion protein, is designed to enhance anti-tumor immune responses and will be tested as both a monotherapy and in combination with other treatments for advanced malignant tumors. Preclinical studies indicate its significant anti-tumor effects and favorable safety profile. This development positions the company strategically in the oncology space, as there are currently no similar products approved domestically or internationally, potentially offering a competitive edge in the market.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. operates in the pharmaceutical industry, specializing in the development of innovative therapies for cancer treatment. The company focuses on creating bifunctional antibody fusion proteins, such as the newly announced JS213, which target advanced malignant tumors.
YTD Price Performance: -9.33%
Average Trading Volume: 1,057,950
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$23.82B
For an in-depth examination of 1877 stock, go to TipRanks’ Stock Analysis page.
